Cargando…

Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application

Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of antica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrayana, Tomi, Wilmer, André, Kurth, Verena, Schmidt-Wolf, Ingo GH, Jaehde, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388145/
https://www.ncbi.nlm.nih.gov/pubmed/28264440
http://dx.doi.org/10.3390/scipharm85010008
_version_ 1782521079646912512
author Hendrayana, Tomi
Wilmer, André
Kurth, Verena
Schmidt-Wolf, Ingo GH
Jaehde, Ulrich
author_facet Hendrayana, Tomi
Wilmer, André
Kurth, Verena
Schmidt-Wolf, Ingo GH
Jaehde, Ulrich
author_sort Hendrayana, Tomi
collection PubMed
description Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of anticancer agents for patients with renal or hepatic dysfunction. A guideline for anticancer agents was developed based on a literature search. An algorithm was generated to enhance the efficiency of the dose adaptation process. Finally, the dosing guideline was converted into an easy-to-use Excel(TM) tool. The concept was applied to a total of 105 adult patients at the Centre for Integrated Oncology, Bonn, Germany. In total, 392 recommendations for dose adaptation were made and 320 (81.6%) recommendations were responded to by the oncologists. 98.4% of the recommendations were accepted. The algorithm simplifies the decision and screening process for high-risk patients. Moreover, it provides the possibility to quickly decide which laboratory tests are required and whether a dose adjustment for a particular anticancer drug is needed. The Excel(TM) tool provides a recommended individual dose for patients with renal or hepatic dysfunction. The effectiveness of this strategy to reduce toxicity should be investigated in further studies before being adopted for routine use.
format Online
Article
Text
id pubmed-5388145
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53881452017-04-14 Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application Hendrayana, Tomi Wilmer, André Kurth, Verena Schmidt-Wolf, Ingo GH Jaehde, Ulrich Sci Pharm Article Most anticancer agents exhibit a narrow therapeutic index, i.e., a small change in plasma concentrations can lead to a less efficacious treatment or an unacceptable degree of toxicity. This study aimed at providing health professionals with a feasible and time-saving tool to adapt the dose of anticancer agents for patients with renal or hepatic dysfunction. A guideline for anticancer agents was developed based on a literature search. An algorithm was generated to enhance the efficiency of the dose adaptation process. Finally, the dosing guideline was converted into an easy-to-use Excel(TM) tool. The concept was applied to a total of 105 adult patients at the Centre for Integrated Oncology, Bonn, Germany. In total, 392 recommendations for dose adaptation were made and 320 (81.6%) recommendations were responded to by the oncologists. 98.4% of the recommendations were accepted. The algorithm simplifies the decision and screening process for high-risk patients. Moreover, it provides the possibility to quickly decide which laboratory tests are required and whether a dose adjustment for a particular anticancer drug is needed. The Excel(TM) tool provides a recommended individual dose for patients with renal or hepatic dysfunction. The effectiveness of this strategy to reduce toxicity should be investigated in further studies before being adopted for routine use. MDPI 2017-02-27 2017 /pmc/articles/PMC5388145/ /pubmed/28264440 http://dx.doi.org/10.3390/scipharm85010008 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hendrayana, Tomi
Wilmer, André
Kurth, Verena
Schmidt-Wolf, Ingo GH
Jaehde, Ulrich
Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title_full Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title_fullStr Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title_full_unstemmed Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title_short Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
title_sort anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388145/
https://www.ncbi.nlm.nih.gov/pubmed/28264440
http://dx.doi.org/10.3390/scipharm85010008
work_keys_str_mv AT hendrayanatomi anticancerdoseadjustmentforpatientswithrenalandhepaticdysfunctionfromscientificevidencetoclinicalapplication
AT wilmerandre anticancerdoseadjustmentforpatientswithrenalandhepaticdysfunctionfromscientificevidencetoclinicalapplication
AT kurthverena anticancerdoseadjustmentforpatientswithrenalandhepaticdysfunctionfromscientificevidencetoclinicalapplication
AT schmidtwolfingogh anticancerdoseadjustmentforpatientswithrenalandhepaticdysfunctionfromscientificevidencetoclinicalapplication
AT jaehdeulrich anticancerdoseadjustmentforpatientswithrenalandhepaticdysfunctionfromscientificevidencetoclinicalapplication